What distinguishes ovarian cancer biologically is its predilection for metastasizing to adipose-rich microenvironments, predominantly the omentum and surrounding peritoneal fat. Historically, investigations into the ovarian tumor microenvironment (TME) have concentrated on immune cells—macrophages, lymphocytes, and related stromal components—leaving the role of adipose tissue and its resident adipose-derived stem cells (ADSCs) largely unexplored. Recent collaborative research spearheaded by scientists at Tongji University has shifted this paradigm by illuminating the pivotal function of senescence in ADSCs as a facilitator of tumor progression. They observed that adipose tissues harvested from ovarian cancer patients frequently exhibit hallmark indicators of cellular senescence, suggesting that these senescent niches may actively support tumor growth rather than merely being passive bystanders.

Employing a comprehensive suite of in vitro cell culture systems alongside rigorously controlled in vivo murine models, investigators demonstrated that ovarian cancer cells induce profound dysfunction within adipose tissue, characterized primarily by the induction of senescence in ADSCs. This senescent state disrupted normal metabolic homeostasis, manifesting as systemic glucose intolerance and insulin resistance. These metabolic abnormalities are not trivial; rather, they create an enabling environment favorable to tumor colonization and dissemination within the peritoneal cavity. Mechanistic analyses pinpointed extracellular vesicles (EVs) secreted by ovarian cancer cells—specifically those enriched with pro-inflammatory cytokines—as critical mediators in this intercellular crosstalk.

One key cytokine identified within the cargo of these ovarian cancer-derived extracellular vesicles (OC-EVs) is interleukin-1 beta (IL-1β), a potent inflammatory molecule. Upon delivery to ADSCs, IL-1β activates the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathway, an essential transcription factor complex involved in immune response regulation and inflammation. This activation triggers a dual cascade: first, it induces ADSCs to enter a senescent phenotype marked by permanent cell cycle arrest and altered secretory profiles; second, it stimulates inflammasome assembly, resulting in amplified secretion of additional inflammatory cytokines such as IL-1β itself and IL-18. This mechanistic loop establishes a self-perpetuating “inflammation-senescence” feedback cycle that drives continuous remodeling of the tumor microenvironment, thereby facilitating tumor progression.

Further validation using clinical adipose tissue specimens from ovarian cancer patients confirmed a strong correlation between the degree of ADSC senescence and disease advancement. Notably, the expression levels of CDKN2A, a recognized molecular marker of senescence encoding the p16^INK4a protein, were significantly elevated in adipose tissue samples from patients with advanced-stage ovarian tumors. This suggests that as ovarian cancer progresses, the senescent state within the adipose microenvironment intensifies, potentially amplifying tumor aggressiveness and metastatic potential. This insight steered the research team to develop innovative strategies aimed at targeting this tumorpromoting senescence to impede ovarian cancer spread.

The first promising therapeutic approach evaluated was the administration of a senolytic drug combination comprising dasatinib and quercetin (referred to as DQ). These agents selectively eliminate senescent cells by disrupting their survival pathways. In a preclinical mouse model of ovarian cancer intraperitoneal metastasis, DQ treatment effectively mitigated ADSC senescence within adipose tissue and concurrently reduced reactive oxygen species (ROS) accumulation, a hallmark of oxidative stress linked to senescence. Remarkably, treatment also restored systemic glucose metabolism and insulin sensitivity. Functionally, these metabolic and microenvironmental improvements translated into a significant reduction in tumor metastatic foci within the peritoneal cavity, indicating a pronounced delay in tumor progression.

Complementing the senolytic strategy, the research team explored resveratrol, a naturally-derived polyphenolic compound known for its antioxidant and anti-inflammatory properties. Resveratrol demonstrated potent inhibition of the NF-κB signaling pathway in ADSCs, directly suppressing the formation of ovarian cancer spheroids—multicellular aggregates resembling tumor architecture. By reversing the senescent phenotype of ADSCs and attenuating adipose tissue inflammation via simultaneous blockade of NF-κB and mitogen-activated protein kinase 3 (MAPK3) pathways, resveratrol exerted dual anti-senescence and anti-tumor effects. In vivo administration substantially alleviated metabolic disturbances, diminished overall tumor burden, and reduced the propensity for peritoneal metastases, highlighting its therapeutic potential.

The ground-breaking insight presented by this research is a shift away from targeting ovarian cancer cells directly. Instead, it focuses on disrupting the tumor’s reliance on senescent adipocytes within the TME, effectively severing the “nutrient supply lines” and metastatic channels critical to tumor survival and dissemination. Conventional anticancer therapies frequently induce senescence in normal stromal cells, paradoxically fostering an environment conducive to cancer recurrence and resistance. By contrast, selectively targeting senescent cells to remodel the microenvironment offers a novel route to overcoming these clinical obstacles.

Importantly, the senolytic agents quercetin and the antioxidant resveratrol, employed in these therapeutic strategies, are both naturally occurring compounds with established safety profiles. Their favorable biosafety positions them as viable candidates for rapid translation into clinical trials. The research team emphasized that future directions will focus on optimizing dosages and administration schedules, exploring combination regimens with existing chemotherapy and immunotherapy protocols, and conducting rigorous clinical investigations to assess efficacy and safety in ovarian cancer patients.

This pioneering study was led by Jia Lü from Shanghai Fourth People’s Hospital, with significant contributions from Associate Researcher Lian Wang of Shanghai Tenth People’s Hospital and Professor Wei Bao of Shanghai General Hospital and Shanghai First Maternity and Infant Hospital. The work was generously supported by multiple funding sources, including substantial grants from the National Natural Science Foundation of China alongside clinical research programs funded by the Shanghai Municipal Health Commission.

In conclusion, this comprehensive investigation highlights the critical role of senescent adipose-derived stromal cells in fostering an inflammatory and metabolically dysregulated microenvironment that promotes ovarian cancer progression. By unraveling the molecular mechanisms underpinning this phenomenon and demonstrating therapeutic reversal via senolytic and anti-inflammatory agents, this study lays the foundation for a transformative approach to managing advanced ovarian cancer. This paradigm shift, targeting the tumor-supportive stromal niche rather than cancer cells alone, promises a new frontier in combating treatment resistance and improving patient survival.

Subject of Research: Ovarian Cancer Tumor Microenvironment and Senescent Adipose-Derived Stem Cells

Article Title: Targeting Senescent ADSCs in Adipose Tissue: Tongji University Team Paves New Way for Ovarian Cancer Therapy

Web References: http://dx.doi.org/10.1007/s11427-024-3060-0

Image Credits: ©Science China Press

Keywords: ovarian cancer, tumor microenvironment, adipose-derived stem cells, cellular senescence, extracellular vesicles, IL-1β, NF-κB signaling, senolytics, dasatinib, quercetin, resveratrol, metabolic reprogramming, intraperitoneal metastasis

The notion that PTMs play a pivotal role in cancer biology is well-established, yet it is the specific implications for ovarian cancer that are beginning to attract significant attention. PTMs include a variety of chemical modifications such as phosphorylation, ubiquitination, glycosylation, and acetylation, each influencing different cellular pathways. For ovarian cancer, these modifications can alter the behavior of tumor cells, granting them the ability to evade apoptosis or acquire resistance to chemotherapeutic agents. By understanding these pathways, researchers hope to identify novel therapeutic strategies that can effectively hinder tumor progression.

In their comprehensive review, Ke and Zhang explore various types of PTMs and their roles in ovarian cancer. Phosphorylation, for instance, is a critical PTM that affects cellular signaling pathways. In ovarian cancer, dysregulated phosphorylation can shift the balance of signaling networks, promoting tumor survival and growth. The authors emphasize the importance of targeting these alterations, suggesting that inhibitors designed to restore normal phosphorylation patterns may yield promising results. This highlights the potential for innovative approaches that could significantly enhance treatment protocols.

Ubiquitination is another focal point of their research that warrants attention. This PTM involves the tagging of proteins for degradation via the proteasome, thereby regulating protein levels within the cell. By manipulating the ubiquitination process, researchers can influence the degradation of oncogenic proteins and stabilize tumor suppressors. Ke and Zhang discuss emerging therapies that aim to modulate ubiquitin pathways, providing a fresh avenue for treatment interventions in ovarian cancer. Such strategies could potentially provide much-needed options for patients who have otherwise limited avenues for effective treatment.

In addition to the established PTMs, the authors delve into the less commonly discussed modifications such as glycosylation and acetylation. These modifications not only affect protein stability and interactions but also contribute to changes in the tumor microenvironment. Glycosylation, for example, can influence immune recognition by masking tumor antigens, thereby facilitating immune evasion. Targeting glycosylation patterns may serve as a strategy to render ovarian tumors more susceptible to immune responses, presenting a new frontier in cancer immunotherapy.

Furthermore, Ke and Zhang address the burgeoning field of clinical applications stemming from basic research into PTMs. As the understanding of these modifications deepens, clinicians are better equipped to utilize this knowledge in designing targeted therapies. The authors advocate for a more personalized approach to ovarian cancer treatment, whereby tumor-specific PTM profiles assist in tailoring therapies that are more effective for individual patients. This strategy could significantly improve treatment outcomes and reduce unnecessary toxicity associated with broad-spectrum chemotherapies.

Interestingly, the implications of targeting PTMs extend beyond direct tumor suppression. The authors also consider the potential for these modifications to be utilized as biomarkers for early detection and prognosis of ovarian cancer. If certain PTMs can be reliably detected in circulating tumor DNA or proteins, they may serve as valuable indicators of disease progression or response to therapy. This bi-directional approach adds an exciting layer to the existing research, merging diagnostic capabilities with therapeutic interventions.

As researchers continue to investigate the underlying mechanisms of PTMs, the interconnectivity with other cellular factors becomes increasingly clear. The authors argue for a broader research agenda that encompasses not only the study of individual PTMs but also their synergistic effects in cancer biology. This holistic view could yield novel insights into the pathways that contribute to ovarian cancer progression and facilitate the development of more comprehensive treatment strategies.

In summary, the work of Ke and Zhang highlights the critical role of post-translational modifications in ovarian cancer, illustrating the intricate mechanisms that underlie tumor biology and resistance. By identifying specific PTMs and developing targeted therapeutic strategies, the researchers provide a blueprint for future studies aiming to improve clinical outcomes for patients with ovarian cancer. As the field progresses, the continued exploration of these modifications offers the promise of groundbreaking advancements in treatment approaches that can ultimately change the trajectory of this challenging disease.

The features of this emerging research spotlight the urgency of advancing our understanding and treatment of ovarian cancer through novel interventions. With ovarian cancer remaining one of the most lethal gynecological malignancies, the need for innovative therapies has never been more critical. The focus on post-translational modifications not only presents a new horizon in understanding cancer mechanisms but also sparks hope for transformative clinical applications that could benefit countless patients in the years to come.

The strides made in this domain symbolize a significant leap toward personalized medicine, where tumor biology is intricately linked with therapy design. As researchers continue to unveil the complexities of ovarian cancer, the integration of such cutting-edge approaches could usher in a new era of effective and targeted treatment options, ultimately leading to better patient prognoses and survival rates.

In conclusion, the exploration of therapeutic targeting of post-translational modifications presents a beacon of hope in the fight against ovarian cancer. Continued research in this area is essential for uncovering the nuances of tumor biology and for developing interventions that may significantly improve patient outcomes. As we stand at the cusp of these promising scientific advancements, the potential for transformative change in ovarian cancer treatment remains tantalizingly within reach.

Subject of Research: Post-Translational Modifications in Ovarian Cancer

Article Title: Therapeutic targeting of post-translational modifications in ovarian cancer: mechanisms and clinical applications

Article References:

Ke, L., Zhang, Y. Therapeutic targeting of post-translational modifications in ovarian cancer: mechanisms and clinical applications.
J Ovarian Res 18, 251 (2025). https://doi.org/10.1186/s13048-025-01833-w

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s13048-025-01833-w

Keywords: Post-Translational Modifications, Ovarian Cancer, Therapeutic Targeting, Cancer Biology, Clinical Applications.